Biogen (BIIB) Stock: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$252.26
1.57 (0.63%)
▲
5d:
+8.04%
30d:
+10.83%
90d:
+22.69%
WAIT
LOW Confidence
Analysis Updated: Oct 26, 2026 12:00 AM ET
Earnings: Oct 28, 2026
TODAY
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BIIB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BIIB shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$387.47
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$240.59
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $252.26, which is considered extended relative to its 30-day fair value range of $218.20 to $235.43. From a valuation perspective, the stock is trading at a premium (Forward PE: 15.3) compared to its historical average (12.1). At these levels, the market is pricing in 8.1% annual earnings growth.
Technical Outlook: Technically, BIIB is in a strong uptrend. The price is approaching resistance at $254.41. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIIB scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BIIB is in a strong uptrend. The price is approaching resistance at $254.41. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: BIIB scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$218.20 -
$235.43
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
22.4%
Protect Your Profits
BIIB is technically overbought (RSI 72). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+7.1% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($247.32)
- BULLISH: Expecting earnings turnaround to 8.1% growth with 3.4% revenue growth
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$218.20 -
$235.43
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$226.71
Resistance Level
$254.41
Current Trend
Strong Uptrend
Technical data as of
Oct 26, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.34
Wall Street Target
$247.32
(-2.0%)
Revenue Growth (YoY)
3.4%
Earnings Growth (YoY)
-84.8%
Profit Margin
8.3%
Valuation Premium vs History
+8.1% premium
PE vs Historical
15.3 vs 12.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+8.1%
(market-implied from PE analysis)
1-Year Target
$272.69
(+8%)
2-Year Target
$294.78
(+17%)
3-Year Target
$318.66
(+26%)
3-Yr Target (if PE normalizes)
(PE: 15→12)
PE COMPRESSION
$251.34
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 33.0%)
$768.43
(+205%)
Base:
(SPY PE: 15.3, Growth: 33.0%)
$593.57
(+135%)
Bear:
(PE: 12.1, Growth: 33.0%)
$468.18
(+86%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (45x PE), but valuation improves significantly next year (15x PE) as earnings recover.
Trailing PE: 44.53 | Current EPS (TTM): $5.63
Bull Case
$551.52
(+119%)
Analyst growth 100.0%, PE expands to 49.0
Base Case
$501.38
(+99%)
Market implied 100.0%, PE stable at 44.5
Bear Case
$170.47
(-32%)
Severe decline -20.0%, PE contracts to 37.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 26, 2026 10:11 PM ET
Data refreshes hourly during market hours. Next update: 11:11 PM
Data refreshes hourly during market hours. Next update: 11:11 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$285 | 46 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1332 | 32 SELL |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$160 | 44 HOLD |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$160 | 56 HOLD |
|
JNJ
Johnson & Johnson |
BUY
23 analysts |
$279 | 63 BUY |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
